학술논문

Chemokine (C-C Motif) Ligand 2 (CCL2) in Sera of Patients with Type 1 Diabetes and Diabetic Complications.
Document Type
Article
Source
PLoS ONE. 2011, Vol. 6 Issue 4, p1-7. 7p.
Subject
*CHEMOKINES
*INFLAMMATORY mediators
*LIGANDS (Biochemistry)
*TREATMENT of diabetes
*DISEASE complications
*PEOPLE with diabetes
*THERAPEUTICS
*MEDICAL care
Language
ISSN
1932-6203
Abstract
Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent. Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay. Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean = 242 ng/ml) compared to patients without any complications (mean = 201 ng/ml) (p = 3.5×10-6). Furthermore, mean serum MCP-1 is higher in controls (mean = 261 ng/ml) than T1D patients (mean = 208 ng/ml) (p<10-23). More importantly, the frequency of subjects with extremely high levels (>99th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio = 0.11, p-33). Conclusion: MCP-1may have a dual role in T1D and its complications.While very high levels of serum MCP-1may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group. [ABSTRACT FROM AUTHOR]